Acute and chronic UV exposure is an important risk factor leading to photocarcinogenesis, photoimmuno suppression and photoaging (1, 2). Patients with Gorlin syndrome (GS) harbour a hereditary predisposition to develop basal cell carcinomas (BCC) and are, therefore, advised that effective sun protection is essential and can help reduce skin cancer risk (1-4). On the other hand, adherence to strict sunprotection habits can result in vitamin D deficiency, which has been demonstrated in many patients with GS (2, 3). Vitamin D deficiency is associated with an increased risk of osteomalacia, bone fractures, autoimmune diseases, cancer and cardiovas cular disease (1). CASE REPORTHere, we report a 54yearold man with GS who was admitted to our hospital for surgical treatment of multiple BCC (Fig. 1). Characteristic features of GS were present in the form of multiple BCC since youth, palmoplantar pits, an odontogenic cyst, calcification of the falx cerebri, and positive family history (5). DNA analysis by multi plex ligationdependent probe amplification revealed a novel heterozygous deletion of exons 11 and 12 within the PTCH1 gene, leading to a frame shift and premature termination codon. Moreover, the patient's medical his tory revealed that within the past decades, multiple bone fractures had occurred after minimal trauma, suggesting a bone calcification disorder. The patient reported of his strict photoprotection habits by daily textile and cosmetic sun protection measures as well as trying to avoid sun exposure. Laboratory workup including parameters of bone turnover and metabolism showed serum 25(OH)D levels of < 4 ng/ml, far below the normal range (30-70 ng/ml), elevated alkaline phosphatase and low serum phosphate concentrations. Serum calcium, parathyroid hormone and vitamin A, E and K concentrations were within normal ranges. Dualenergy Xray absorptiometry (DEXA) was consistent with severe osteoporosis ac cording to the WHO classification, with a mean T-score of -3.6 measured from the hip (Fig. 2). Based on these observations, we concluded that the patient suffered from a disorder of bone mineralisation caused by vitamin D deficiency. Substitution therapy was initiated with a single dose of intramuscularly administered vitamin D3 derivative (cholecalciferol 100,000 IU) followed by longterm daily oral substitution of 2,000 IU of vitamin D3. The 25(OH)D level was within the normal range 3 months after initiation of therapy.Vitamin D deficiency has been described in GS pa tients and is thought to be related to strict sun protection habits (1-3). The time of vitamin D measurement in our patient was spring (April), where probands usually have higher vitamin D levels than during winter (2), but they were still below the detection limit of the labora tory test. Normal serum levels of the other lipophilic vitamins (vitamins A, E, K) argue against an intestinal malabsorption disorder or an imbalanced overall nu tritional vitamin supply in our patient. There were no signs of renal or hepatic insufficiency which could have...
Diagnoses of cutaneous lymphomas belong to a vast spectrum of differential diagnoses. This registry describes frequent findings and shows rare variants. You can only diagnose what you know; accordingly, a collection of case reports, which we wish to encourage, can help in processing and specification of entities.
Purpose: BAY 86-4367 is a new directly F-18 labeled, synthetic bombesin analog (3-Cyano-4-[18F]fluorobenzoyl-Ala(SO3H)-Ala(SO3H)-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2) with antagonistic properties, targeting Gastrin-releasing-peptide receptors (GRPr). The aim of this proof of mechanism (PoM) study is to demonstrate the feasibility, safety, tolerability, biodistribution and diagnostic performance of the PET tracer BAY 86-4367 in patients with primary prostate cancer. Methods: 5 patients with non-treated primary prostate cancer (PSA range 7 to 24 µg/l) were prospectively included in the study. All patients had standardized biopsy proven primary prostate cancer with Gleason scores ranging from 6 (3+3) to 9 (4+5). All patients had standardized sequential dynamic and static PET/CT using the F-18 labeled tracer BAY 86-4367 for primary staging. Safety data (vital signs, ECG, adverse effects) were assessed in all patients. Four patients had a prior PET/CT scan with F-18 choline. Patients were scheduled for prostatectomy of primary prostate cancer. Full prostate samples were histopathologically analyzed to further confirm the imaging localisation data. Results: The tracer BAY 86-4367 was well tolerated after injection of ∼300 MBq and a peptide mass dose <40 µg per patient. Safety data showed no relevant changes in the sequential blood values, electrocardiograms, urine testing or physical examination. Malignant lesions were depicted in 3/5 patients with the F-18 labeled BAY 86-4367 tracer. Biopsy verified the correct tumor localisation of these imaging findings. In two patients with histologically proven primary prostate cancer, BAY 86-4367 showed no active accumulation in the prostate. F-18 choline PET/CT was performed in 4/5 patients with positive signals in all 4 patients. Correlation with biopsy showed correct localisation of F-18 choline in tumor tissue. However, there was false positive F-18 choline accumulation in benign hyperplasia of the prostate. Conclusion: PET imaging with the F-18 labeled bombesin analog BAY 86-4367 is safe. The tracer BAY 86-4367 correctly depicts primary prostate cancer in a subset of patients. However, diagnostic accuracy of bombesin analogs in GRPr imaging needs to be further explored. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4139. doi:10.1158/1538-7445.AM2011-4139
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.